The origins of the Innovative Medicines Initiative (IMI) lie in the European Technology Platform on Innovative Medicines that was supported under the European Commission's Sixth Framework Programme for Research (FP6) as a gathering of stakeholders, led by the pharmaceutical industry and it was launched in 2008. Its main goal is that delivering the right prevention and treatment for the right patient at the right time by improving new generation vaccines, drugs and terapies. Besides developing more effective treatments and therapies, it will reduce the burden of public healthcare systems and by improving coordination between health sector it will provide more safer and faster clinical trials. Through the IMI-2 programme, it has a 3.3 Billion Euro budget for the period 2014-2024.
IMI-2 (PPP) Vision
The right prevention and treatment for the right patient at the right time
IMI-2 (PPP) Mission
- Improve the current drug development process by providing support for the development of tools, standards and approaches to assess efficacy, safety and quality of regulated health products
- Develop diagnostic and treatment biomarkers for diseases clearly linked to clinical relevance and approved by regulators
- Reduce the time to reach clinical proof of concept in medicine development, such as for cancer, immunological, respiratory, neurological and neurodegenerative diseases
- Increase the success rate in clinical trials of priority medicines identified by the World Health Organisation
- Develop new therapies for diseases for which there is a high unmet need, such as Alzheimer’s disease and limited market incentives, such as antimicrobial resistance
- Reduce the failure rate of vaccine candidates in phase III clinical trials through new biomarkers for initial efficacy and safety checks
Who can join IMI-2 (PPP)?
Universities, drug companies and ındustries, SME’s, patient organisations, non-profit organisations and other legal entities
- Antimicrobial Resistance
- Cardiovascular Diseases
- Neurodegenerative Diseases
- Psychiatric Diseases
- Respiratory Diseases
- Immune-mediated Diseases
- Ageing-associated Diseases
- Rare/Orphan Diseases
EFPIA Member Organisations participate IMI-2 projects. Most of the companies are below:
- Fachverband der Chemischen Industrie Österreichs (FCIO), Pharma.be, The Danish Association of the Pharmaceutical Industry (LIF), Pharma Industry Finland (PIF), Les Enterprises du Medicament (LEEM), Verband Forschender Arzneimittelhersteller (VfA), Hellenic Association of Pharmaceutical Companies (SfEE), Irısh Pharmaceutical Healthcare Association (IPHA), Associazione delle imprese del farmaco (Farmindustria), Norwegian Association of Pharmaceutical Manufacturers (LMI)
Turkish Members of IMI-2 (PPP)
How can be a member of IMI-2 (PPP)
Join IMI as an Associated Partner
Under the IMI 2 programme, any legal entity (except for EFPIA companies) can become an IMI Associated Partner.Like EFPIA partners in IMI projects, Associated Partners do not receive any funding from IMI, but contribute to the projects, mainly through in-kind contributions (such as their experts’ time, access to resources / equipment). As contributors to the project, Associated Partners are involved in the definition of the project, and can participate as observers in IMI Governing Board meetings during discussions relating to the projects they are involved in.
Template for organisations that want to apply to become Associated Partners link
IMI-2 (PPP) Roadmap Elements
Organisations can suggest ideas for IMI projects by filling in a simple form. Organisations that choose this option should be aware that if their idea is adopted and ultimately used in an IMI Call for proposals, they will have to apply for funding like any other organisation.
To suggest ideas link